CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its DISCOVERY trial, a screening study examining the prevalence of transthyretin (TTR) mutations in patients suspected of having cardiac amyloidosis. With this study, Alnylam aims to identify and facilitate the diagnosis of familial amyloidotic cardiomyopathy (FAC). Alnylam is advancing ALN-TTRsc, an investigational candidate targeting TTR for the treatment of patients with TTR cardiac amyloidosis, including FAC – which is caused by mutations in TTR – and senile systemic amyloidosis (SSA) – which is caused by idiopathic amyloid deposition of wild-type TTR in the heart.
Help employers find you! Check out all the jobs and post your resume.
